Kailera Therapeutics is trading 4.17% down at $10.57, with no specific catalyst established. - No verified company-specific news has been linked to the October 2, 2026 decline. - The broader market is higher, so the stock’s move does not appear to track the positive direction. - Phase 1 ribupatide injection-site data presented at EASD was announced October 1 and does not explain the decline.